Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.

Johnson & Johnson has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of its EGFRxMET bispecific antibody, for all the indications approved for the current, intravenous formulation.

Subcutaneous administration takes less time and is tied to fewer administration-related reactions than intravenous.

New Afrezza prescribing information outlines higher starting dose conversions for patients transitioning from mealtime insulin to improve glycemic control.

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation ...

For more than a century, oral insulin has been considered a "dream" therapy for diabetes, hindered by enzymatic degradation in the digestive tract and the absence of a dedicated intestinal transport ...

Scientists are developing a microneedle patch that they hope could someday simplify IVF hormone delivery. They've tested it ...

The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...